Doray Pharmaceuticals: intends to transfer all equity of its subsidiary to Tibet Jiakang

Doray pharmaceutical announcement, the company signed a "equity transfer agreement" with Tibet Jiakang, intending to transfer 100% equity of Wuhan Doray, 100% equity of Hairui Di, and 69% equity of Ruitilian to Tibet Jiakang. After the completion of this equity transfer, the company will no longer hold equity in Wuhan Doray, Hairui Di, and Ruitilian, and Wuhan Doray, Hairui Di, and Ruitilian will no longer be included in the company's consolidated financial statements.